108 related articles for article (PubMed ID: 36094691)
21. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
John CS; Fong A; Alban R; Gillen J; Moore KM; Walsh CS; Li AJ; Rimel BJ; Amersi F; Cass I
Gynecol Oncol; 2022 Jan; 164(1):202-207. PubMed ID: 34862065
[TBL] [Abstract][Full Text] [Related]
22. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
[TBL] [Abstract][Full Text] [Related]
23. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
[TBL] [Abstract][Full Text] [Related]
24.
Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
[TBL] [Abstract][Full Text] [Related]
25. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
[TBL] [Abstract][Full Text] [Related]
26. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
27. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
28. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
29. Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond
Fanale D; Incorvaia L; Filorizzo C; Bono M; Fiorino A; Calò V; Brando C; Corsini LR; Barraco N; Badalamenti G; Russo A; Bazan V
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32854451
[TBL] [Abstract][Full Text] [Related]
30. Second Primary Breast Cancer in Young Breast Cancer Survivors.
Brantley KD; Rosenberg SM; Collins LC; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Warner E; Come SE; Zheng Y; Kirkner GJ; Snow C; Winer EP; Partridge AH
JAMA Oncol; 2024 Apr; ():. PubMed ID: 38602683
[TBL] [Abstract][Full Text] [Related]
31. Mutational profile of hereditary breast and ovarian cancer - Establishing genetic testing guidelines in a developing country.
Krivokuca A; Mihajlovic M; Susnjar S; Spasojevic IB; Minic I; Popovic L; Brankovic-Magic M
Curr Probl Cancer; 2022 Feb; 46(1):100767. PubMed ID: 34284872
[TBL] [Abstract][Full Text] [Related]
32. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
Pohl-Rescigno E; Hauke J; Loibl S; Möbus V; Denkert C; Fasching PA; Kayali M; Ernst C; Weber-Lassalle N; Hanusch C; Tesch H; Müller V; Altmüller J; Thiele H; Untch M; Lübbe K; Nürnberg P; Rhiem K; Furlanetto J; Lederer B; Jackisch C; Nekljudova V; Schmutzler RK; Schneeweiss A; Hahnen E
JAMA Oncol; 2020 May; 6(5):744-748. PubMed ID: 32163106
[TBL] [Abstract][Full Text] [Related]
33. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
[TBL] [Abstract][Full Text] [Related]
34. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing.
Chapman BV; Liu D; Shen Y; Olamigoke OO; Lakomy DS; Barrera AMG; Stecklein SR; Sawakuchi GO; Bright SJ; Bedrosian I; Litton JK; Smith BD; Woodward WA; Perkins GH; Hoffman KE; Stauder MC; Strom EA; Arun BK; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):437-444. PubMed ID: 34582940
[TBL] [Abstract][Full Text] [Related]
35. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Tedaldi G; Tebaldi M; Zampiga V; Danesi R; Arcangeli V; Ravegnani M; Cangini I; Pirini F; Petracci E; Rocca A; Falcini F; Amadori D; Calistri D
Oncotarget; 2017 Jul; 8(29):47064-47075. PubMed ID: 28423363
[TBL] [Abstract][Full Text] [Related]
36. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
Akcay IM; Celik E; Agaoglu NB; Alkurt G; Kizilboga Akgun T; Yildiz J; Enc F; Kir G; Canbek S; Kilic A; Zemheri E; Ezberci F; Ozcelik M; Dinler Doganay G; Doganay L
Int J Cancer; 2021 Jan; 148(2):285-295. PubMed ID: 32658311
[TBL] [Abstract][Full Text] [Related]
37. Importance of multigene panel test in patients with consanguineous marriage and family history of breast cancer.
Ozmen V; Caglayan AO; Yararbas K; Ordu C; Aktepe F; Ozmen T; Ilgun AS; Soybir G; Alco G; Tsaousis GN; Papadopoulou E; Agiannitopoulos K; Pepe G; Kampouri S; Nasioulas G; Sezgin E; Soran A
Oncol Lett; 2022 Apr; 23(4):118. PubMed ID: 35261632
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
39. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
40. Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis.
Anaclerio F; Pilenzi L; Dell'Elice A; Ferrante R; Grossi S; Ferlito LM; Marinelli C; Gildetti S; Calabrese G; Stuppia L; Antonucci I
Front Genet; 2023; 14():1060504. PubMed ID: 37065479
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]